Avascular Necrosis Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: April 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 639.82 Million |
|
Revenue Forecast in 2031 |
US$ 1,061.84 Million |
|
CAGR |
5.79% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global avascular necrosis therapeutics market was valued at US$ 639.82 million in 2022 and is expected to register a revenue CAGR of 5.79% to reach US$ 1,061.84 million by 2031.
Avascular Necrosis Therapeutics Market Fundamentals
Avascular necrosis (AVN), or osteonecrosis, is a condition where bone tissue dies due to a lack of blood supply. It can affect any bone in the body but most commonly affects the hip joint. Several factors can lead to avascular necrosis, including injury, excessive alcohol consumption, long-term steroid use, and certain medical conditions such as sickle cell anemia and lupus. In some cases, the cause of avascular necrosis is unknown. Symptoms of avascular necrosis can include pain in the affected joint that may worsen with activity, limited range of motion, and difficulty bearing weight on the affected joint. Treatment options vary depending on the severity of the condition but can include medication, physical therapy, and surgery in more severe cases. Early diagnosing and treating avascular necrosis is important to prevent damage to the affected bone and joint.
Avascular necrosis is classified into traumatic avascular necrosis, non-traumatic avascular necrosis, post-radiation avascular necrosis, and post-transplantation avascular necrosis. An injury or trauma to the bone causes traumatic AVN. For example, a fracture or dislocation can disrupt the blood supply to the bone and lead to AVN. Non-traumatic AVN occurs without an obvious injury or trauma to the bone. It is often associated with underlying medical conditions, such as sickle cell disease, systemic lupus erythematosus, or alcoholism. This type of AVN occurs without a clear cause. It is most commonly found in the hip joint of middle-aged adults and is often referred to as primary AVN. Post-radiation AVN occurs as a complication of radiation therapy for cancer. The radiation can damage the blood vessels that supply the bone, leading to AVN. Post-transplantation AVN occurs after a bone marrow or solid organ transplant. The medications that suppress the immune system can affect the blood supply to the bone, leading to AVN. The treatment of AVN depends on the stage and severity of the disease. In some cases, conservative treatments such as pain management, physical therapy, and assistive devices may be sufficient. In more advanced cases, surgical interventions such as core decompression, bone grafting, or joint replacement can be necessary.
[22]
Avascular Necrosis Therapeutics Market Dynamics
The increased prevalence of avascular necrosis due to alcohol or caffeine intake or cigarettes in the growing population is the primary factor driving significant revenue growth in the avascular necrosis therapeutics market. A rise in the likelihood of numerous chronic illnesses such as diabetes, sexually transmitted infections, or major consequences from chemotherapy and gland transplants raises the likelihood of avascular necrosis. It hence correlates to the expansion of the avascular necrosis therapeutics market. The increased use of performance-enhancing medications in various treatment choices raises the chance of avascular necrosis, boosting revenue growth in the avascular necrosis therapeutics market.
Hip injury difficulties, such as deterioration or fractures, can obstruct blood circulation to the bone, leading to trauma-related avascular necrosis, which promotes avascular necrosis surgery adoption trends. The global avascular necrosis therapeutics market revenue is expected to be driven by alarming cases of hip fractures, automotive accidents, and excessive alcohol intake. The avascular necrosis therapeutics market revenue is expected to grow as more people become aware of non-invasive avascular necrosis therapies. Even though this health disease is silent and idiopathic, it is increasing the responsibility of the patient population and affects people of all ages. The avascular necrosis therapeutics market revenue will grow as research and development activities increase to continue developing revolutionary medicine. Other significant driving factors of the global avascular necrosis therapeutics market revenue include technical advancements for better osteonecrosis medical therapy and an increased ask for non-invasive remedies. Technological advancements in avascular necrosis intervention, as well as a rise in medication development and research for diagnostics, all contribute to the growth of the avascular necrosis therapeutics market revenue.
Furthermore, advances in implant technology have led to more durable and long-lasting implants that can improve patient outcomes and reduce the need for revision surgeries. This drives demand for newer and more advanced bone implants in the Avascular necrosis therapeutics market revenue. Increasing healthcare expenditure in developed and developing countries allows for greater investment in joint replacement surgeries and bone implants, which contributes to the growth of the bone implants segment in the avascular necrosis therapeutics market revenue.
However, treatment for AVN can be expensive, particularly if surgical intervention is required. This can be a significant barrier to access for some patients, especially in developing countries with limited healthcare resources. AVN is a relatively rare condition, and there may be limited awareness and understanding among both patients and healthcare providers. This can lead to delays in diagnosis and treatment, which can worsen patient outcomes. While joint replacement surgery can effectively manage AVN, non-surgical treatments such as medications and physical therapy have limited effectiveness. Some of the risk factors for AVN, such as genetics, cannot be modified or controlled. This can make it difficult to prevent the development of AVN in at-risk populations. Joint replacement surgery carries risks such as infection, blood clots, and implant failure. These complications can be challenging to manage and lead to poor patient outcomes.
Avascular Necrosis Therapeutics Market Ecosystem
The global avascular necrosis therapeutics market is analyzed from three perspectives: drug class, distribution channel, and region.
Avascular Necrosis Therapeutics Market by Drug Class
Based on drug class, the global avascular necrosis therapeutics market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), cholesterol-lowering drugs, bisphosphonates, blood thinners, and others.
The bisphosphonates segment accounts for the largest revenue share in the global market and is expected to continue to dominate the global market during the forecast period from 2023 to 2031. Avascular necrosis most commonly affects the hip joint yet can also occur in other joints such as the knee, shoulder, and ankle. Medications such as bisphosphonates and statins are commonly used to treat avascular necrosis. They help slow the disease's progression by improving blood flow to the affected bone and reducing inflammation. These medications are often prescribed alongside other treatments, such as physical therapy and surgery.
Non-steroidal anti-inflammatory drugs (NSAIDs such as aspirin (Bufferin), ibuprofen (Advil), and naproxen (Aleve) help to reduce inflammation and provide pain relief. Alendronate has short-term efficacy in reducing pain, improving articular function, slowing bone collapse progression, and delaying total hip arthroplasty in adults with AVN. Similarly, Iloprost, a vasoactive prostaglandin analog licensed for inhalational therapy of pulmonary hypertension, has shown clinical and radiographic improvements in early-stage AVN when delivered intravenously. Iloprost causes vasodilation and enhances microcirculation, lowering bone marrow edema and alleviating pain and other symptoms; it inhibits platelet aggregation and lowers the quantity of oxygen-free radicals and leukotrienes.
In addition, the medication segment of the avascular necrosis therapeutics market revenue is expected to grow due to the increasing prevalence of this condition worldwide and the development of new and innovative drugs that are more effective in treating avascular necrosis. This rise in revenue share is driven by the rising awareness of avascular necrosis and the increasing demand for better treatment options by patients and healthcare providers. Thus, all these factors are responsible for the revenue growth of the medication segment, thereby propelling the global avascular necrosis therapeutics market revenue.
Avascular Necrosis Therapeutics Market by Distribution Channel
[1456]
Based on the distribution channel, the global avascular necrosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies registered the largest revenue share in the global market in 2022. Hospital pharmacies are well-equipped to provide the necessary medication for AVN patients because they typically stock a wide range of drugs used to treat various medical conditions. In addition, hospital pharmacies have the expertise to manage complex medication regimens and monitor patients for potential drug interactions or side effects. Furthermore, hospitals often serve as referral centers for AVN patients, meaning they receive many patients with this condition. This drives demand for AVN medications and makes hospital pharmacies a critical component of the AVN treatment landscape.
Avascular Necrosis Therapeutics Market by Region
Based on the region, the global avascular necrosis therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has a relatively high incidence of AVN, which drives demand for avascular necrosis treatments market. This can be attributed to aging populations, obesity, and the prevalence of risk factors such as steroid use and alcohol abuse. North America has a highly developed healthcare infrastructure, with advanced hospitals and healthcare facilities well-equipped to diagnose and treat AVN. This includes access to advanced imaging technology and surgical techniques that effectively manage AVN. Moreover, this region has a well-established pharmaceutical industry, which allows for the development and availability of advanced AVN treatments. In addition, there is a strong focus on research and development in this region, which leads to discovering new treatments and therapies for AVN. Furthermore, this region also has a high level of healthcare spending, which allows for greater investment in AVN treatments and research. This helps to drive innovation and ensure that patients have access to the latest and most effective treatments for AVN.
Competitive Landscape
The prominent players operating in the global avascular necrosis therapeutics market are:
Strategic Development
The bisphosphonates segment dominates the global avascular necrosis therapeutics market with the largest revenue share.
The global avascular necrosis therapeutics market is expected to register a revenue CAGR of 5.79% during the forecast period.
Asia Pacific is expected to be the fastest-growing region in the global avascular necrosis therapeutics market.
Pfizer Inc., Merck & Co. Inc., Novartis AG, and Sanofi SA are the key market players operating in the global avascular necrosis therapeutics market.
The expected size of the avascular necrosis therapeutics market is US$ 1,061.84 million in 2031.
*Insights on financial performance are subject to the availability of information in the public domain